Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|22|39|6039-6054

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.39, 2016-12, pp. : 6039-6054

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PI3K/AKT/mTOR Inhibitors In Ovarian Cancer

By  

Current Medicinal Chemistry, Vol. 17, Iss. 36, 2010-12 ,pp. : 4433-4447

Bentham Science Publishers

Access to resources Recommend Favorite

Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer

By  

Current Medicinal Chemistry, Vol. 21, Iss. 26, 2014-09 ,pp. : 3070-3080

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies

By Barrett David   Brown Valerie I.   Grupp Stephan A.   Teachey David T.  

Pediatric Drugs, Vol. 14, Iss. 5, 2012-10 ,pp. : 299-316

Adis International

Access to resources Recommend Favorite

PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress

By  

Current Medicinal Chemistry, Vol. 17, Iss. 35, 2010-12 ,pp. : 4326-4341

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

By Martelli Alberto M   Evangelisti Camilla   Chiarini Francesca   Grimaldi Cecilia   Manzoli Lucia   McCubrey James A  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 9, 2009-09 ,pp. : 1333-1349

Informa Healthcare

Access to resources Recommend Favorite